Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sesterterpenes | 2 | 2015 | 3 | 0.240 |
Why?
|
| Claudin-5 | 1 | 2024 | 3 | 0.240 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2024 | 7 | 0.240 |
Why?
|
| Cadmium | 1 | 2024 | 12 | 0.230 |
Why?
|
| Cell Adhesion | 1 | 2024 | 206 | 0.220 |
Why?
|
| Keratan Sulfate | 2 | 2013 | 2 | 0.210 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 2 | 2013 | 3 | 0.210 |
Why?
|
| Pseudomonas Infections | 2 | 2013 | 51 | 0.200 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2013 | 100 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 69 | 0.150 |
Why?
|
| Endoscopy | 1 | 2019 | 98 | 0.150 |
Why?
|
| Urban Population | 1 | 2019 | 180 | 0.150 |
Why?
|
| Octamer Transcription Factors | 1 | 2015 | 2 | 0.130 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2015 | 14 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 152 | 0.120 |
Why?
|
| Photoaffinity Labels | 1 | 2014 | 5 | 0.110 |
Why?
|
| Keratitis | 1 | 2013 | 9 | 0.100 |
Why?
|
| Hypoxia | 1 | 2014 | 112 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 33 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 386 | 0.100 |
Why?
|
| Macrophages, Peritoneal | 1 | 2012 | 73 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 88 | 0.090 |
Why?
|
| Fas Ligand Protein | 1 | 2011 | 39 | 0.090 |
Why?
|
| Phagocytosis | 1 | 2012 | 260 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2011 | 149 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 628 | 0.080 |
Why?
|
| Caloric Restriction | 1 | 2007 | 16 | 0.070 |
Why?
|
| Ghrelin | 1 | 2007 | 18 | 0.070 |
Why?
|
| Insulin | 1 | 2011 | 673 | 0.070 |
Why?
|
| Stomach | 1 | 2007 | 83 | 0.070 |
Why?
|
| Tight Junctions | 1 | 2024 | 20 | 0.060 |
Why?
|
| Mice | 6 | 2015 | 10300 | 0.060 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2024 | 38 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2015 | 374 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2024 | 307 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2024 | 173 | 0.050 |
Why?
|
| Lumican | 2 | 2013 | 2 | 0.050 |
Why?
|
| Aging | 1 | 2007 | 710 | 0.050 |
Why?
|
| Animals | 6 | 2015 | 19664 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2013 | 645 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 446 | 0.040 |
Why?
|
| New York City | 1 | 2019 | 75 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 495 | 0.040 |
Why?
|
| Helicobacter Infections | 1 | 2019 | 55 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 58 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2014 | 942 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2013 | 1997 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 42 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 217 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 119 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 194 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 82 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 648 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 450 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 365 | 0.030 |
Why?
|
| CD18 Antigens | 1 | 2012 | 30 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 289 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2382 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 402 | 0.020 |
Why?
|
| Humans | 4 | 2024 | 59437 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 805 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 143 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 235 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 172 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 1555 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 114 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 145 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2011 | 190 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 1302 | 0.020 |
Why?
|
| Immune System | 1 | 2011 | 129 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 516 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 627 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 1151 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 5126 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 619 | 0.020 |
Why?
|
| Female | 3 | 2019 | 30757 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1206 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2007 | 29 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 6078 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 986 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 1232 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 851 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2051 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 13423 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 2458 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 15695 | 0.010 |
Why?
|
| Middle Aged | 1 | 2019 | 16332 | 0.010 |
Why?
|
| Male | 1 | 2019 | 27775 | 0.010 |
Why?
|